Hospitals can reduce the risk of life-threatening bloodstream infections in children with peripherally inserted central venous catheters by assessing daily the patient’s progress and removing the device as early as possible, according to a new Johns Hopkins Children’s Center study published online March 31 in the journal Clinical Infectious Diseases.

The findings will be presented on Saturday, April 2, at the annual meeting of the Society for Healthcare Epidemiology of America.

The study, believed to be the largest one to date of its kind in pediatric patients, analyzed predictors of catheter-related bloodstream infections among 1,800 children treated at Hopkins over six years. The children cumulatively underwent more than 2,590 catheter insertions, which resulted in a total of 116 infections.

One potent predictor of infection was length of use, the researchers found. Children whose devices remained in for three weeks or longer were 53 percent more likely to get a bloodstream infection, compared with those with shorter catheter times. Children who got the catheters to receive IV nutrition were more than twice as likely to get an infection as children who had the devices placed for other reasons.

A peripherally inserted central venous catheter, or “PICC” line, is a tube inserted into a peripheral blood vessel, usually in the arm, and threaded toward major blood vessels near the lungs and heart.

The catheter serves as a temporary portal for medications, food, fluids and blood draws. However, with prolonged use, the line can become contaminated and give dangerous bacteria entry into a patient’s blood stream.

The findings of the study underscore the need for a tailored approach to each patient while at the same time following standard infection prevention guidelines, the investigators say.

“Clinicians should evaluate each patient’s condition daily and weigh the risk of leaving the device in against the risk of removing it by asking a simple question ‘Does this child need a central line for another day?’” says senior author Aaron Milstone, M.D., M.H.S., an infectious disease specialist at Hopkins Children’s.

No matter the length of PICC use, the researchers say, the first line of defense against bloodstream infections should always be simple precautions that include rigorous hand-washing before handling the line, regularly changing the dressing that covers the PICC line, and periodically changing the tubes and caps attached to it.

“Even when clinicians follow meticulously basic rules of catheter insertion and maintenance, the risk of infection is never zero,” Milstone said. “Reducing the time a child has a PICC is one extra step to minimize that risk.”

When researchers compared patients in intensive care with those on regular units, they found an 80 percent higher risk of bloodstream infections among children in intensive care. However, the study showed that more than 30 percent of all infections occurred in children outside of the intensive-care unit, a finding that underscores the need for vigilant monitoring of all children with PICC lines. About one-fifth (22 percent) of infections occurred after patients left the hospital, the researchers found, a finding that points to the importance of educating both parents and home-based caregivers on ways to prevent infections at home.

“Children in intensive care have more severe disease and often require catheters, but it is critical that we remain vigilant about patients with perceived ‘lower risk’ outside of intensive care, and indeed those outside of the hospital, because they are not immune to infections,” says lead investigator Sonali Advani, M.B.B.S., M.P.H.

While hospitals have recently made great strides in reducing the number of central line infections, thousands of people continue to die from them each year, the researchers say.

###

Other investigators in the study included Nicholas Reich, Ph.D., Arnab Sengupta, M.B.B.S., M.P.H., and Leslie Gosey, R.N., M.S., all of Hopkins.

The research was funded by the NIH.

Conflict-of-interest disclosure: Milstone has received grant support from Sage, a manufacturer of disposable healthcare products, and BioMerieux, which makes testing and diagnostic devices. The terms of these agreements are managed by The Johns Hopkins University in accordance with its conflict-of-interest policies.

###

Contact: Ekaterina Pesheva
.(JavaScript must be enabled to view this email address)
410-516-4996
Johns Hopkins Medical Institutions